Home » TMLT Blog » Tygacil — Label Changes to Address Increased Risk of Death

Tygacil — Label Changes to Address Increased Risk of Death

June 21, 2013

The FDA notified health care professionals of a new boxed warning describing an increased risk of death when intravenous Tygacil is used.

These changes to the Tygacil prescribing information are based on an analysis that showed a higher risk of death among patients receiving Tygacil compared to other antibacterial drugs: 2.5% (66/2640) vs. 1.8% (48/2628), respectively. The adjusted risk difference for death was 0.6% with corresponding 95% confidence interval (0.0%, 1.2%). In general, the deaths resulted from worsening infections, complications of infection, or other underlying medical conditions.

Tygacil is approved to treat complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia.

Health care professionals should reserve Tygacil for situations in which alternative treatments are not suitable.

Health care professionals are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.

September 27, 2013 — FDA safety alert

Low Molecular Weight Heparins — Recommendations to Decrease Risk of Epidural Hematomas

The FDA is recommending to carefully consider the timing of spinal catheter placement and removal in patien...

200,000 Bottles of Infant Motrin Recalled

McNeil Consumer Healthcare Division is voluntarily recalling at the retail level 200,000 bottles of Concent...

Tygacil — Label Changes to Address Increased Risk of Death

Previous Article

Next Article

Tygacil — Label Changes to Address Increased Risk of Death

Previous Article

Next Article

Most Recent Articles

Texas physicians will soon be required to check the Texas Prescription Monitoring database before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol.

A panel of experts will discuss how to manage risks related to protected health information. The webinar is presented by Cyber Trust Alliance and features TMLT’s cyber expert John Southrey.

The Food and Drug Administration (FDA) has initiated an investigation into the health risk of brain deposits following repeated use of gadolinium-based contrast units (GBCAs) for MRI

TMLT is monitoring a legal situation that could adversely affect Texas physicians.

Medefense covers legal expenses, fines, and penalties associated with disciplinary actions, such as actions by the TMB, a hospital review committee, or a federal regulatory agency.

During the renewal process, physicians are required to answer questions regarding any status changes since their last renewal. Certain answers or omissions can trigger an investigation by the board.

During registration, physicians must answer questions regarding any status changes since their last renewal. However, certain answers or omissions can trigger an investigation by the Board.

The team works together during the year to raise money for a local charity selected by the group.

To follow up on the post New Mexico legislature acts to protect patients’ access to care in Texas from February 26, the legislation states that New Mexico will enforce choice of law and jurisdiction a

The U.S. Food and Drug Administration (FDA) is enforcing stricter regulations for surgical mesh products used in transvaginal procedures to repair pelvic organ prolapse (POP). The products are being r

On February 7, 2018, the Food and Drug Administration cleared an update to the design and labeling for Pentax ED-3490TK duodenoscopes. Recommendations included.

As cyber attacks in health care continue, many practices may be asking this question.

EHR company Allscripts is still working to recover from a ransomware attack on Thursday, January 18, affecting two of its national data centers.

TMLT to offer one $10,000 scholarship.

If you experienced a HIPAA breach that affected fewer than 500 individuals in 2017, the deadline to report that breach to HHS is the end of February.

The FDA is requiring safety labeling changes to limit the use of prescription cough and cold medicines containing opioids in patients younger than 18 years old.

Protecting sensitive data involves a variety of physical safeguards.